Dr. Goy on Changing Treatment Landscape of Mantle Cell Lymphoma

Andre Goy, MD, MS
Published: Monday, Dec 19, 2016



Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses how the treatment landscape of mantle cell lymphoma (MCL) is evolving.

The clinical presentation of MCL, Goy explains, is one that is very heterogeneous. This is due to the biology of the disease as well as the comorbidities associated with patients, as their ages range from mid-60s to early 70s, he adds. This also explains why there are more than 12 treatment options for patients with MCL in the NCCN guidelines.

However, it is difficult for many of these therapies to be explored in large phase III studies, Goy says. Additionally, the majority of patients receiving induction chemotherapy do relapse and develop resistance to chemotherapy. Over the years, research has been conducted to improve the responses and decrease relapse.

By looking at real-world data with dose-intensity approaches with or without stem cell transplant consolidation upfront, there is a complete response rate of more than 80% versus 30% with standard therapies, he adds.


Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses how the treatment landscape of mantle cell lymphoma (MCL) is evolving.

The clinical presentation of MCL, Goy explains, is one that is very heterogeneous. This is due to the biology of the disease as well as the comorbidities associated with patients, as their ages range from mid-60s to early 70s, he adds. This also explains why there are more than 12 treatment options for patients with MCL in the NCCN guidelines.

However, it is difficult for many of these therapies to be explored in large phase III studies, Goy says. Additionally, the majority of patients receiving induction chemotherapy do relapse and develop resistance to chemotherapy. Over the years, research has been conducted to improve the responses and decrease relapse.

By looking at real-world data with dose-intensity approaches with or without stem cell transplant consolidation upfront, there is a complete response rate of more than 80% versus 30% with standard therapies, he adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x